Predictive factors of head and neck squamous cell carcinoma patient tolerance to high‑dose cisplatin in concurrent chemoradiotherapy

Nakano,Kenji; Sato,Yasuyoshi; Toshiyasu,Takashi; Sato,Yukiko; Inagaki,Lina; Tomomatsu,Junichi; Sasaki,Toru; Shimbashi,Wataru; Fukushima,Hirofumi; Yonekawa,Hiroyuki; Mitani,Hiroki; Kawabata,Kazuyoshi; Takahashi,Shunji

doi:10.3892/mco.2015.687

Predictive factors of head and neck squamous cell carcinoma patient tolerance to high‑dose cisplatin in concurrent chemoradiotherapy

Authors:
- Kenji Nakano
- Yasuyoshi Sato
- Takashi Toshiyasu
- Yukiko Sato
- Lina Inagaki
- Junichi Tomomatsu
- Toru Sasaki
- Wataru Shimbashi
- Hirofumi Fukushima
- Hiroyuki Yonekawa
- Hiroki Mitani
- Kazuyoshi Kawabata
- Shunji Takahashi
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Radiation Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Head and Neck Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan
Published online on: November 25, 2015 https://doi.org/10.3892/mco.2015.687
Pages: 303-309

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although high‑dose cisplatin is the standard regimen of concurrent chemoradiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (HNSCC), varying levels of patient tolerance towards cisplatin have been reported, and the predictive factors of cisplatin tolerance remain to be elucidated. The present study retrospectively reviewed newly diagnosed HNSCC patients who received CCRT. Cisplatin (80 mg/m2) was administered every 3 weeks. The proportion of high‑dose cisplatin‑tolerant patients (cumulative cisplatin dose, ≥200 mg/m2) was determined, and the predictive factors of cisplatin tolerance were analyzed in a logistic regression analysis. Between June 2006 and March 2013, a total of 159 patients were treated with CCRT. The median follow‑up time was 36.7 months. A total of 73 patients (46%) tolerated a cumulative cisplatin dose ≥200 mg/m2; male gender [odds ratio (OR), 25.00; P=0.005] and high body surface area (BSA) (>1.80 m2; OR, 2.21; P=0.032) were significantly predictive of high‑dose cisplatin tolerance. The high‑dose cisplatin‑tolerant patients had a significantly higher complete response (CR) rate (82 vs. 67%, P=0.045); however, there were no significant between‑group differences in the 3‑year OS (79.5 vs. 81.2%, P=0.59) or PFS (70.4 vs. 44.6%, P=0.076) by cisplatin tolerance. In clinical practice, approximately one‑half of the patients tolerated high‑dose cisplatin in CCRT. Male gender and high BSA could be predictive of cisplatin tolerance.

View Figures

View References

1	Brizal DM and Esclamado R: Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: Consensus, controversy and conundrum. J Clin Oncol. 24:2612–2617. 2006. View Article : Google Scholar : PubMed/NCBI
2	Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley DF, Schuller DE and Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemothardiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
3	Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III Randomized Intergroup Study 0099. J Clin Oncol. 16:1310–1317. 1998.PubMed/NCBI
4	Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003. View Article : Google Scholar : PubMed/NCBI
5	Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
6	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:226–247. 2009. View Article : Google Scholar
7	Zenda S, Onozawa Y, Tahara M, Kawashima M, Shikama N, Sasaki S and Boku N: Feasibility study of single agent cisplatin and concurrent radiotherapy in japanese patients with squamous cell carcinoma of the head and neck: Preliminary results. Jpn J Clin Oncol. 37:725–729. 2007. View Article : Google Scholar : PubMed/NCBI
8	Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, et al: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 31:845–852. 2013. View Article : Google Scholar : PubMed/NCBI
9	Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, et al: Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: Long-term report of efficacy and toxicity. J Clin Oncol. 32:3858–3866. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ang KK: Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: Are we addressing burning subjects? J Clin Oncol. 22:4657–4659. 2004. View Article : Google Scholar : PubMed/NCBI
11	Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK and Chan AT: Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 104:300–304. 2012. View Article : Google Scholar : PubMed/NCBI
12	Ghi MG, Paccagnella A, Floriani I and Garavaglia D: Concomitant chemoradiation in locally advanced head and neck squamous cell carcinoma: A literature-based meta-analysis on the platinum concomitant chemotherapy. J Clin Oncol. 29(Suppl): 55342011.
13	Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, et al: Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage iii to iv head and neck carcinomas: RTOG 0522. J Clin Oncol. 32:2940–2950. 2014. View Article : Google Scholar : PubMed/NCBI
14	Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, et al: Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 81:915–922. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ley J, Mehan P, Wildes TM, Thorstad W, Gay HA, Michel L, Nussenbaum B, Trinkaus K and Adkins D: Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. Oncology. 85:290–296. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol. 31:853–859. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ghi MG, Paccagnella A, Ferrari D, Foa P, Rocca MC, Verri E, Maiello E, Azzaello G, D'Ambrosio C, Casanova C, et al: A phase II–III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Efficacy results (NCT0186826). J Clin Oncol. 31(suppl): abstr. 60032013.
18	Meyer F, Fortin A, Wang CS, Liu G and Bairati I: Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 82:1454–1462. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silvia I, Leon DA and Smeeth L: Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults. Lancet. 384:755–765. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sparano JA, Wang M, Zhao F, Stearns V, Martion S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, et al: Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 118:5937–5946. 2012. View Article : Google Scholar : PubMed/NCBI
21	Weiss L, Melchard T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R and Egle A: Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol. 25:171–176. 2014. View Article : Google Scholar : PubMed/NCBI
22	Dahlberg SE, Schiller JH, Bonomi PB, Sanler AB, Brahmer JR, Ramalingam SS and Johnson DH: Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern cooperative oncology group clinical trials. J Thorac Oncol. 8:1121–1127. 2013. View Article : Google Scholar : PubMed/NCBI
23	Arthur AE, Peterson KE, Rozek LS, Tayloe JM, Light E, Chepeha DB, Hébert JR, Terrell JE, Wolf GT and Duffy SA: UM Head and Neck SPORE Program: Pretreatment dietary patterns, weight status and head and neck squamous cell carcinoma prognosis. Am J Clin Nutr. 97:360–368. 2013. View Article : Google Scholar : PubMed/NCBI
24	McRackan TR, Watkins JM, Herrin AE, Garrett-Mayer EM, Sharma AK, Day TA and Gillespie MB: Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 118:1180–1185. 2008. View Article : Google Scholar : PubMed/NCBI
25	Takenaka Y, Takemoto N, Nakahara S, Yamamoto Y, Yasui T, Hanamoto A, Fukusumi T, Michiba T, Cho H, Yamamoto M and Inohara H: Prognostic significance of body mass index before treatment of head and neck cancer. Head and Neck. 37:1518–1523. 2015. View Article : Google Scholar : PubMed/NCBI
26	Chen SW, Yang SN, Liang JA and Lin FJ: The outcome and prognostic factors in patients with aspiration pneumonia during concurrent chemoradiotherapy for head and neck cancer. Eur J Cancer Care (Engl). 19:631–635. 2010. View Article : Google Scholar : PubMed/NCBI
27	Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, et al: Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. Head and Neck. 36:120–125. 2014. View Article : Google Scholar : PubMed/NCBI
28	Mortensen HR, Jensen K and Grau C: Aspiration pneuonia in patients treated with radiotherapy for head and neck cancer. Acta Oncologica. 52:270–276. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ottosson S, Lindblom U, Wahlberg P, Nilsson P, Kjellén E, Zackrisson B, Levring Jäghagen E and Laurell G: Weight loss and body mass index in relation to aspiration in patients treated for head and neck cancer: A long-term follow-up. Support Care Cancer. 22:2361–2369. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
31	Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI and Cullen KJ: Survival and human papillomavirus in oropharynx cancer in TAS 324: A subset analysis from an international phase III trial. Ann Oncol. 22:1071–1077. 2011. View Article : Google Scholar : PubMed/NCBI